Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 4, 2013, Pages 721-728

  Shilkrut, Mark ^a   McLaughlin, P William ^a   Merrick, Gregory S ^b   Vainshtein, Jeffrey M ^a   Feng, Felix Y ^a   Hamstra, Daniel A ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b WHEELING JESUIT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; CALCIUM COMPOUNDS; DISEASES; HAZARDS; MULTIVARIANT ANALYSIS; RISK ASSESSMENT; UROLOGY;

ANDROGEN DEPRIVATION THERAPY; CLINICAL CHARACTERISTICS; EXTERNAL BEAM RADIATION THERAPY; HIGH-RISK PROSTATE CANCERS; INTER QUARTILE RANGES; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; PROSTATE SPECIFIC ANTIGEN;

RADIOTHERAPY;

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; BIOCHEMISTRY; CANCER MORTALITY; CANCER PROGNOSIS; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME;

EID: 84879200199     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.03.028     Document Type: Article

References (16)

1. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial JAMA 294 2005 1233 1239
2. A. Al-Mamgani, W.L. van Putten, and W.D. Heemsbergen Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 72 2008 980 988
3. L. Collette, T. Burzykowski, and F.H. Schroder Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials Eur J Cancer 42 2006 1344 1350
4. J.W. Denham, A. Steigler, and C. Wilcox Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: Evidence from the TROG 96.01 randomised controlled trial Lancet Oncol 9 2008 1058 1068
5. J.P. Ciezki, C.A. Reddy, and J. Garcia PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time Int J Radiat Oncol Biol Phys 64 2006 512 517
6. M.K. Buyyounouski, T. Pickles, and L.L. Kestin Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer J Clin Oncol 30 2012 1857 1863
7. R.K. Valicenti, M. DeSilvio, and G.E. Hanks Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of Radiation Therapy Oncology Group Protocol 92-02 Int J Radiat Oncol Biol Phys 66 2006 1064 1071
8. M.K. Buyyounouski, A.L. Hanlon, and E.M. Horwitz Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy Int J Radiat Oncol Biol Phys 70 2008 59 66
9. N.S. Kapadia, K. Olson, and H.M. Sandler Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancer Cancer 118 2012 2059 2068
10. M.K. Buyyounouski, A.L. Hanlon, and D.F. Eisenberg Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer Int J Radiat Oncol Biol Phys 63 2005 1455 1462
11. M. Shilkrut, G.S. Merrick, and P.W. McLaughlin The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer Cancer 119 2013 681 690
12. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
13. A. Pollack, G.K. Zagars, and G. Starkschall Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial Int J Radiat Oncol Biol Phys 53 2002 1097 1105
14. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
15. D.A. Hamstra, K. Bae, and M.V. Pilepich Older age predicts decreased metastasis and prostate cancer-specific death for men treated with radiation therapy: Meta-analysis of radiation therapy oncology group trials Int J Radiat Oncol Biol Phys 81 2011 1293 1301
16. D.A. Loblaw, K.S. Virgo, and R. Nam Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline J Clin Oncol 25 2007 1596 1605